





Dear Colleagues,

We hope you will join us virtually on October 19-20, 2021 for ***Africa Liver Cancer Guidelines***.

We are excited to bring together colleagues in Africa and from around the world together to develop the liver cancer diagnosis, prevention, and treatment guidelines to help improve outcomes for all liver cancer patients in Africa. We aim to publish the guidelines, distribute them throughout Africa, and present them at major medical meetings.

We are pleased to share that **registration for this program is complimentary** for all attendees.

Sincerely,

**Ghassan K. Abou-Alfa, MD, MBA**

Conference Chair  
Memorial Sloan Kettering Cancer Center

**Ashraf Omar, MD**

Conference Vice-Chair  
University of Cairo

[mskcc.org/AfricaLiverGuidelines](https://mskcc.org/AfricaLiverGuidelines)  
[#AfricaLiverGuidelines](https://twitter.com/AfricaLiverGuidelines)



## OVERVIEW

**Liver cancer is the fourth most common cancer for both genders in Africa.** Viewed as a whole, the risk factors in Africa are similar to those encountered in other parts of the world. However, these risk factors appear to differ by region. **Many of the risk factors could be avoided with comprehensive national strategies, medical advice, and personal decisions that are guided by appropriate education.** Prevention strategies include vaccination against hepatitis B and the fight against aflatoxin. In Africa, where majority of the countries are low-middle income the costly nature of these measures remain an impediment.

The **overall survival of liver cancer stands out at only 3 months in Africa** compared to other regions in the world. This is mainly driven by **late-stage presentation and limited access to the most novel therapeutic approaches.** The hands-on experience of several members of the steering committee about the limited available options or the applicability of alternative approaches for surveillance and therapy would help validate the appropriate and accessible management. The combination of local risk factors, economics, culture, and potentially biology create a unique environment for each region. Therefore, the **guidelines designed for one environment may not translate well to another.** This justifies the critical need for prevention, early detection and treatment guidelines that reflect the available and alternative options across the continent.

A key element of the proposed initiative is to **join the entire African continent under the same guidelines with added distribution, based on geo-economic GDP per capita regions.** An example is the NCCN Harmonized Guidelines for Sub-Saharan Africa, which is based on the NCCN North America guidelines, but highlight solely the available treatment options in Sub-Saharan Africa. The Middle East North Africa (MENA) region NCCN initiatives aim to cover Northern Africa.

## LIVE VIRTUAL FORMAT

This live conference will take place virtually over two half-days and will be delivered using Zoom. The program will consist of introductory lectures from experts in Africa and the United States as well as interactive sessions where all attendees are encouraged to provide input in helping to build liver cancer guidelines for Africa. We are excited to bring together colleagues in Africa and from around the world to help with this initiative.

**After this program, we aim to publish the guidelines, distribute them throughout Africa, and present them at major medical meetings.** We anticipate the need to host this program annual to continue analyzing the effectiveness of the guidelines.

### **DAY 1: October 19<sup>th</sup>**

7:00-11:05 AM (New York)

11:00 AM-3:05 PM (GMT)

### **DAY 2: October 20<sup>th</sup>**

7:00 AM-12:00 PM (New York)

11:00 AM-4:00 PM (GMT)

## WHO SHOULD ATTEND

We invite experts of all disciplines who care for patients with primary liver cancer, hepatocellular carcinoma, or HCC with an interest of the disease in Africa to attend this conference.

## EDUCATIONAL OBJECTIVES

- Affirm current correct prevention and therapeutic practices
- Rectify and update current prevention and therapeutic practices
- Develop joint African continent HCC guidelines for surveillance, prevention, and treatment
- Evaluate guidelines based on geo-economic GDP per capita regions

[mskcc.org/AfricaLiverGuidelines](https://mskcc.org/AfricaLiverGuidelines)  
[#AfricaLiverGuidelines](https://twitter.com/AfricaLiverGuidelines)

## CONFERENCE CHAIR

---



**Ghassan K. Abou-Alfa, MD, MBA**

Professor  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

## CONFERENCE VICE CHAIR

---



**Ashraf Omar, MD**

Professor  
University of Cairo  
Cairo, Egypt

### FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

[mskcc.org/AfricaLiverGuidelines](https://mskcc.org/AfricaLiverGuidelines)  
[#AfricaLiverGuidelines](https://twitter.com/AfricaLiverGuidelines)

# FACULTY

## **Mary Afihene, MD**

Faculty, Professor  
Signetcare Medical Services  
Kumasi, Ghana

## **Adwoa Afrakoma Agyei-Nkansah, MD**

Faculty, Professor  
University of Ghana  
School of Medicine and Dentistry  
Accra Ghana

## **Olusegun Isaac Alatise, MD**

Faculty, Professor  
Obafemi Awolowo University Teaching  
Hospital Complex  
Ile-Ife, Nigeria

## **Akwi Asombang, MD**

Faculty, Professor  
Massachusetts General Hospital  
Harvard Medical School  
Boston, MA, USA

## **Fiyinfolu (Folu) Balogun, MD**

Faculty, Professor  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

## **Alain Bougouma, MD**

Faculty, Professor  
Centre Hospitalier Universitaire Yalgado  
Burkina Faso

## **Adda Bounedjar, MD**

Chairman of Medical Oncology  
Anti Cancer Center  
Blida, Algeria

## **Lina Cunha, MD**

Faculty, Professor  
Hospital Privado De Maputo  
Maputo, Mozambique

## **Lisa M. DeAngelis, MD**

Physician-in-Chief and Chief Medical Officer  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

## **Papa Saloum Diop, MD**

Faculty, Professor  
Université Cheikh Anta DIOP  
Dakkar, Senegal

## **Reda Elwakil, MD**

Emeritus Professor of Tropical Medicine  
Faculty, Professor  
Ain Shams University  
Cairo, Egypt

## **Eloumou Bagnaka Servais Albert Fiacre, MD**

Head of Internal Medicine Unit  
Douala University  
Douala, Cameroon

## **Eduard Jonas, MD**

Faculty, Professor  
UCT Private Academic Hospital  
Cape Town, South Africa

## **Stephen Kimani, MD**

Faculty, Professor  
University of North Carolina at Chapel Hill  
Chapel Hill, NC, USA

## **Peter Kingham, MD**

Faculty, Professor  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

## **Reshad Kurrimbukus, MD**

Faculty, Professor  
Jeetoo Hospital and Bruno Cheong Hospital  
Port Louis, Mauritius

## **Hailemichael Desalegn Mekonnen, MD**

Faculty, Professor  
St. Paul's Hospital Millennium Medical College  
Addis Ababa, Ethiopia

## **Ali Mahamat Moussa Ali, MD**

Faculty, Professor  
University of N'Djamena  
Chad

## **Ntokozi Ndlovu, MD**

Faculty, Professor  
University of Zimbabwe College of  
Health Sciences  
Harare, Zimbabwe

## **Jerry Ndumbalo, MD**

Faculty, Professor  
Ocean Road Cancer Institute  
Dar es Salaam, Tanzania

## **Lewis Roberts, MD**

Advisor, Faculty, Professor  
Mayo Clinic  
Rochester, MN, USA

## **Vikash Sewram,**

**PhD (Public Health & Fam. Med.), MPH (Epidemiol.)**  
Faculty, Professor, Director  
African Cancer Institute, Stellenbosch University  
Cape Town, South Africa

## **Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD**

Faculty, Professor  
University of Cape Town  
Cape Town, South Africa

## **Precious Takondwa Makondi, MBBS, PhD**


Faculty, Professor  
Kamuzu Central Hospital - National Cancer Center  
Lilongwe, Malawi

## **Christian Tzeuton, MD**

Faculty, Professor  
Yaounde University and Douala University  
Cameroon

## **Ju Dong Yang, MD**

Advisor, Faculty, Professor  
Cedars-Sinai Medical Center  
Los Angeles, CA, USA



# SCHEDULE

## TUESDAY, OCTOBER 19<sup>TH</sup>

6:45 AM	Virtual Conference Check-in
7:00 AM	<b>Conference Introduction</b> Ghassan K. Abou-Alfa, MD, MBA
7:10 AM	<b>Conference Welcome</b> Lisa M. DeAngelis, MD
7:15 AM	<b>HBV Prevention and Vaccination</b> Lewis Roberts, MD
7:35 AM	<b>HCV Prevention and Treatment</b> Ashraf Omar, MD
7:55 AM	<b>NASH Prevention</b> Vikash Sewram, PhD (Public Health & Fam. Med.), MPH (Epidemiol.)
8:15 AM	<b>Open Forum Discussion Prevention and Vaccination</b> CHAIR: Ju Dong Yang, MD
9:15 AM	Break
9:30 AM	<b>North and South Diagnosis</b> Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD
9:50 AM	<b>North and South Therapies</b> Adda Bounedjar, MD
10:10 AM	<b>Open Forum Discussion North and South Proposed Diagnosis and Therapy Guidelines</b> CHAIR: Ntokozo Ndlovu, MD
11:10 AM	<b>Closing Remarks</b> Lewis Roberts, MD
11:15 AM	Adjourn



# SCHEDULE

WEDNESDAY, OCTOBER 20 <sup>TH</sup>	
6:45 AM	Virtual Conference Check-in
7:00 AM	<b>Opening Remarks</b> Ashraf Omar, MD
7:05 AM	<b>Central Diagnosis</b> Christian Tzeuton, MD
7:25 AM	<b>Central Therapies</b> Precious Takondwa Makondi, MBBS, PhD
7:45 AM	<b>Open Forum Discussion</b> <b>Central Proposed Diagnosis and Therapy Guidelines</b> CHAIR: Akwi Asombang, MD
8:45 AM	Break
9:05 AM	<b>East and West Diagnosis</b> Hailemichael Desalegn Mekonnen, MD
9:25 AM	<b>East and West Therapies</b> Jerry Ndumbalo, MD
9:45 AM	<b>Open Forum Discussion</b> <b>East and West Proposed Diagnosis and Therapy Guidelines</b> CHAIR: Mary Afihene, MD
10:45 AM	Break
10:55 AM	<b>Open Forum Discussion</b> <b>Reflections, Publication, Follow-Up Next Steps</b> CHAIRS: Ghassan K. Abou-Alfa, MD, MBA Ashraf Omar, MD
11:55 AM	<b>Closing Remarks</b> Ghassan K. Abou-Alfa, MD, MBA
12:00 PM	Adjourn



Registration for this program is complimentary for all to attend. Register online at:

**[mskcc.org/AfricaLiverGuidelines](https://mskcc.org/AfricaLiverGuidelines)**

---

## ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **AMA Credit Designation Statement**

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **8.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **ABIM MOC Recognition Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **8.00 Medical Knowledge MOC points and patient safety MOC credit** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Memorial Sloan Kettering  
Cancer Center

